[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100352761":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":27,"responsibleParty":42,"collaborators":46,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of Rome Tor Vergata","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"patients with solid tumor",null,"All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http:\u002F\u002Fwww.sicog.it\u002F).",[13],{"name":14,"affiliation":15,"role":16},"Mario Roselli","Tor Vergata University Hospital","STUDY_CHAIR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Vincenzo Formica, MD, PhD","CONTACT","+390620908190","v.formica1@gmail.com",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Cristiano Serci","+390620903247","cserci81@gmail.com",[28],{"facility":15,"status":29,"city":30,"state":10,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Rome","00133","Italy","IT",{"type":35,"coordinates":36},"Point",[37,38],12.51133,41.89193,{"lat":38,"lon":37},[41],{"name":24,"role":20,"phone":21,"phoneExt":10,"email":10},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Vincenzo Formica","Consultant in Medical Oncology, Principal Investigator",[47],{"name":48,"class":6},"S.I.C.O.G. partners","100352761","body-mass-index-bmi-and-quality-of-life-qol-in-cancer-patients-100352761",false,"NCT03873064","Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients","BMI-QoL","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of solid tumor\n2. Age \\>18 years\n3. Signed informed consent\n4. Life expectancy \\> 12 weeks\n\nExclusion Criteria:\n\n1. Inability to fill out the EORTC QLQ-C30 questionnaire.\n2. Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs)\n3. Diagnosis of second malignancies that might bias results interpretation","ALL","18 Years",{"count":59,"type":60},1380,"ESTIMATED","OBSERVATIONAL","BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated.\n\nHigh BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).",[64,65,66],"Neoplasm Malignant","Body Weight","Quality of Life",[68,69,70,71],"BMI","EORTC QLQ-C30","metastatic cancer","localized cancer","2024-02-01",{"date":74,"type":75},"2024-02-02","ACTUAL",{"date":77,"type":75},"2019-01-15",{"date":79,"type":60},"2034-01-15",{"name":5,"class":6},1]